The current nicotine dependence market consists of a wide range of over-the-counter products, yet only two prescription drugs are approved for this indication. Despite the availability of these treatments, nicotine dependence remains a chronically relapsing condition with only a minority of patients achieving permanent abstinence in an initial attempt to quit.

In February 2006, the FDA granted Fast Track status to NicVAX for use as a therapeutic for smoking cessation, thereby affirming that the FDA views nicotine dependence as a significant unmet need. NicVAX consists of 3'-aminomethylnicotine bound to Pseudomonas aeruginosa exoprotein A, an exotoxin that has been made non-toxic by an amino acid deletion. The vaccine is designed to stimulate the production of antibodies which prevent nicotine from crossing the blood-brain barrier and entering the brain.

Nabi has previously stated that it intends to seek a commercialization partner and/or obtain external funding for the development of NicVAX. With Phase III trials planned to start by the end of 2008, these latest results should attract greater interest from large pharmaceutical companies looking to enter the lucrative nicotine dependence market.

With the launch now predicted for 2011, Datamonitor anticipates NicVAX to be the first vaccine to enter the nicotine dependence market. Its novel mechanism of action is expected to generate strong interest among physicians and, assuming a licensing deal, Datamonitor forecasts the drug to achieve sales of almost $700m by 2012 across the seven major markets. However, from 2012 onwards, Novartis's NIC-002 therapeutic vaccine is expected to offer stiff competition, restricting further sales growth.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

If you do not have Internet access, the U.S./Canada call-in number is 866-510-0676 and the international call-in number is 617-597-5361. The passcode is 88486207. An audio replay will be available for U.S./Canada callers at 888-286-8010 and for international callers at 617-801-6888. The replay passcode is 74880581. This audio replay also will be available through August 14, 2008. The press release and an archived version of the webcast will be available on the company's website at http://www.nabi.com.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(r) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse, and PentaStaph(tm) (Pentavalent S. aureus Conjugate Vaccine), a vaccine designed to prevent the most dangerous and prevalent strains of S. aureus bacterial infections. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit our Web site:http://www.nabi.com.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Nabi Biopharmaceuticals

Nabi Biopharmaceuticals
          Investor Relations
          301-770-3099
          www.nabi.com

    * Zero start-up fees and lower discount fees;
    * Quick, simple online patient application, payment processing and
      reporting;
    * A program designed to maximize patient approvals;
    * Prompt payment to provider bank accounts.

Benefits for patients include:

    * Simple online application;
    * No-interest, cash and low-interest payment plan options at low
      rates which enable patients to pay for dental care in
      installments and still get the care they need right now.

"We're excited to bring the Patient Payment Program to the dental industry, as it provides a variety of financing options to both dental providers and their patients that increase operational efficiencies and make it affordable for patients to receive and pay for dentist-recommended services," stated Yousuf Nabi, VP of Sales and Marketing. "Our program offers the lowest rate among the competitors in our space and reliable customer service support for patients. As a dental EDI provider with more than 18 years of experience in revenue cycle management and connectivity solutions, DentalXChange is now able to offer practices the complete package solution: streamlined connectivity and advanced business applications merged with a competitive patient financing program."

About Dentalxchange.com

Dentalxchange.com, a pioneer in web-based dental EDI solutions, is a vanguard provider of optimal connectivity, streamlined technology and transaction solutions for patients, payers and providers. Designed to simplify and improve efficiency in business processes, our solutions enable healthcare providers to focus on the highest quality of customer and patient care for a superior dental experience. For more information, please visit, www.Dentalxchange.com.

The Dentalxchange.com logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=5019

About the EHG Fund:

Established in 2004 by the EDI Health Group, Inc., the EHG Fund seeks to financially assist institutions and programs in the realms of healthcare, education and human services in order to improve the quality of life for men, women and children worldwide. The EHG Fund has worked to build joint partnerships with organizations such as the Orange County Community Foundation and Full Circle Learning, Inc., to better serve communities and people in the United States, Asia, Africa and all over the globe. For more information, please visit www.Dentalxchange.com.

The EHG Fund logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=5020

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Dentalxchange.com

Integrity Public Relations, Inc.
         Jacqueline Tait
         949-768-4423 ext. 804
         jackie@integritypr.net
 
         DentalXChange.com
         Yousuf Nabi, VP, Sales and Marketing
         ynabi@dentalxchange.com

The significant improvement in net loss from continuing operations was due to operating expense reductions of 43% for both the quarter and six months ended June 28, 2008 compared to 2007. These reductions reflect the Company's efforts to reduce infrastructure costs as well as its reduced scale of operations.

Net cash used in operating activities from continuing operations was $13.1 million for the first six months of 2008, a 48% improvement compared to $25.3 million used in the first six months of 2007. Cash, cash equivalents and marketable securities totaled $160.6 million at June 28, 2008. This balance includes $1.0 million owed to Biotest Pharmaceuticals Corporation related to sales of Nabi-HB, but excludes $10.1 million of restricted cash related to discontinued operations. This restricted cash is held in escrow to support any valid indemnification claims made by Biotest and the balance of this account will be released to Nabi in April 2009. To date, Biotest has not asserted any indemnification claims.

During the second quarter, the Company repurchased $31.6 million, par value, of its 2.875% convertible senior notes for $28.9 million, a $2.7 million discount, resulting in a $1.8 million gain on retirement of debt.

"Our financial results continue to meet our forecasts for reduced operating costs and cash utilization targets for both the second quarter and the year to date and we also further strengthened the balance sheet through a significant reduction of our debt at a discount to par value," said Dr. Raafat Fahim, President and Chief Executive Officer of Nabi Biopharmaceuticals. "I am also very pleased with the recently announced positive interim results from our NicVAX Phase 2 immunogenicity study which supports our hypothesis that production of anti-nicotine antibodies can be significantly enhanced by including an additional dose to the immunization regimen. These results are essential to the design of the pivotal Phase 3 clinical trials which we plan to initiate by the end of this year. Further, our strategic alternatives process is progressing with interest from several parties. We remain focused on maximizing the value of our assets for the benefit of our shareholders."

Financial Results Conference Call and Webcast Information

The Company will host a live webcast at 4:30 p.m. EDT today to discuss these results.

The live webcast can be accessed at: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=1904345 (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your browser. Remove the space if one exists.) or via the Nabi Biopharmaceuticals website at http://www.nabi.com.

If you do not have Internet access, the U.S./Canada call-in number is 866-510-0676 and the international call-in number is 617-597-5361. The passcode is 88486207. An audio replay will be available for U.S./Canada callers at 888-286-8010 and for international callers at 617-801-6888. The replay passcode is 74880581. This audio replay also will be available through August 15, 2008. An archived version of the webcast will be available on the company's website at http://www.nabi.com.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(r) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse, and PentaStaph(tm) (Pentavalent S. aureus Vaccine), a vaccine designed to prevent the most dangerous and prevalent strains of S. aureus bacterial infections. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.

Forward-Looking Statements

Statements in this release that are not strictly historical are forward-looking statements including statements about the strategic alternatives process, development of our product candidates, and clinical trials and studies. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to: successfully pursue strategic and other alternatives; obtain successful clinical trial results; receive PhosLo milestone and royalty proceeds; successfully partner with third parties to fund, develop, and manufacture our pipeline products, including NicVAX and our gram-positive infections products; realize anticipated cost saving; attract and maintain the human and financial resources to bring to market products in development; depend upon third parties to manufacture our products; achieve approval and market acceptance of our products; enter into and maintain arrangements with third parties to market and sell our products; comply with reporting and payment obligations under government rebate and pricing programs; raise additional capital on acceptable terms, or at all; and re-pay our outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in the company's Annual Report on Form 10-K for the fiscal year ended December 29, 2007 and the Quarterly Report for the quarter ended March 29, 2008 on Form 10-Q filed with the Securities and Exchange Commission.

                      Nabi Biopharmaceuticals
               CONDENSED CONSOLIDATED BALANCE SHEETS
                            (Unaudited)

                           (In thousands)

                                                 June 28,   December 29,
                                                  2008          2007
                                                ---------   ------------
  ASSETS
  Current assets:
     Cash and cash equivalents                  $ 160,550     $ 217,606
     Marketable securities                             --         1,600
     Prepaid expenses and other current assets      1,769         2,371
     Restricted cash related to discontinued
      operations                                   10,123            --
     Assets of discontinued operations              1,425         4,616
                                                ---------     ---------
         Total current assets                     173,867       226,193
  Property and equipment, net                       1,568         1,971
  Other assets                                        313           379
  Restricted cash related to discontinued
   operations                                          --        10,027
                                                ---------     ---------
  Total assets                                  $ 175,748     $ 238,570
                                                =========     =========
  LIABILITIES AND STOCKHOLDERS' EQUITY
  Current liabilities:
     Trade accounts payable                     $   1,048     $   3,647
     Accrued expenses and other current
      liabilities                                   4,070         7,105
     Current liabilities of discontinued
      operations                                    4,294         9,548
                                                ---------     ---------
         Total current liabilities                  9,412        20,300
  2.875% convertible senior notes, net             40,989        71,738
                                                ---------     ---------
  Total liabilities                                50,401        92,038
  Commitments and contingencies
  Stockholders' equity:
     Convertible preferred stock                       --            --
     Common stock                                   6,228         6,212
     Capital in excess of par value               335,836       333,527
     Treasury stock                               (40,503)      (23,608)
     Accumulated deficit                         (176,214)     (169,599)
                                                ---------     ---------
         Total stockholders' equity               125,347       146,532
                                                ---------     ---------
  Total liabilities and stockholders' equity    $ 175,748     $ 238,570
                                                =========     =========


                     Nabi Biopharmaceuticals
        CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                          (Unaudited)

            (In thousands, except per share amounts)


                                For the Three         For the Six
                                 Months Ended         Months Ended
                             June 28,   June 30,  June 28,    June 30,
                               2008       2007      2008        2007
                             --------   --------  --------   ---------
  Operating expenses:
    General and
     administrative
     expenses                 $ 2,927    $ 6,380   $ 8,060    $ 14,680
    Research and
     development
     expenses                   3,344      4,685     6,549      10,773
                             --------   --------  --------   ---------
  Operating loss               (6,271)   (11,065)  (14,609)    (25,453)

    Interest income             1,217      1,419     3,255       2,999
    Interest expense             (434)      (855)     (999)     (1,729)
    Other income (expense),
     net                        1,816          3     1,947           2
                             --------   --------  --------   ---------
  Loss from continuing
   operations before
   income taxes                (3,672)   (10,498)  (10,406)    (24,181)
    Income taxes                   --         --        --        (190)
                             --------   --------  --------   ---------
  Loss from continuing
   operations                  (3,672)   (10,498)  (10,406)    (24,371)
  Discontinued operations:
    Net income from
     discontinued operations    3,296      2,606     3,790       5,822
    Net gain (loss) on
     disposal of discontinued
     operations                    --      3,114        --       2,742
                             --------   --------  --------   ---------
  Income from discontinued
   operations                   3,296      5,720     3,790       8,564
                             --------   --------  --------   ---------
  Net loss                    $  (376)   $(4,778)  $(6,616)   $(15,807)

  Basic and diluted (loss)
   income per share:

    Continuing operations     $ (0.07)   $ (0.17)  $ (0.20)   $  (0.40)
    Discontinued operations      0.06       0.09      0.07        0.14

  Basic and diluted (loss)
   income per share           $ (0.01)   $ (0.08)  $ (0.13)   $  (0.26)
                             ========   ========  ========   =========
  Basic and diluted weighted
   average shares
   outstanding                 51,498     61,280    52,235      61,192
                             ========   ========  ========   =========


                       Nabi Biopharmaceuticals
           CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                            (Unaudited)

                          (In thousands)


                                                For the Six Months Ended
                                                ------------------------
                                                   June 28,    June 30,
                                                    2008         2007
                                                 ----------  ----------
  Cash flow from operating activities:
    Loss from continuing operations              $ (10,406)  $ (24,371)
    Adjustments to reconcile loss from
     continuing operations to net
     cash used in operating activities
     from continuing operations:
    Depreciation and amortization                      291       1,000
    Non-cash compensation                            1,943       1,205
    Gain on repurchase of convertible senior
     notes                                          (1,817)         --
    Other                                               93          98
    Changes in assets and liabilities:
    Prepaid expenses and other assets                  598        (821)
    Trade accounts payable, accrued expenses
     and other                                      (3,789)     (2,424)
                                                 ---------   ---------
    Total adjustments                               (2,681)       (942)
                                                 ---------   ---------
  Net cash used in operating activities from
   continuing operations                           (13,087)    (25,313)
  Net cash (used in) provided by operating
   activities from discontinued operations            (517)      6,455
                                                 ---------   ---------
  Net cash used in operating activities            (13,604)    (18,858)
                                                 ---------   ---------
  Cash flow from investing activities:
    Purchases of marketable securities                  --     (28,500)
    Proceeds from sales of marketable securities     1,600      25,575
    Capital expenditures                               (20)        (54)
    Proceeds from sales of assets                       91          --
                                                 ---------   ---------
  Net cash (used in) provided by investing
   activities from continuing operations             1,671      (2,979)
  Net cash provided by investing activities
   from discontinued operations                      2,500       3,368
                                                 ---------   ---------
  Net cash provided by investing activities          4,171         389
                                                 ---------   ---------
  Cash flow from financing activities:
    Proceeds from issuance of common stock for
     employee benefit plans                             54         536
    Purchase of common stock for treasury          (18,658)         --
    Repurchase of convertible senior notes         (28,914)
    Other financing activities                         (82)         --
                                                 ---------   ---------
  Net cash (used in) provided by financing
   activities from continuing operations           (47,600)        536
  Net cash (used in) provided by financing
   activities from discontinued operations             (23)        223
                                                 ---------   ---------
  Net cash (used in) provided by financing
   activities                                      (47,623)        759
                                                 ---------   ---------
  Net decrease in cash and cash equivalents        (57,056)    (17,710)
  Cash and cash equivalents at beginning of
   period                                          217,606      86,227
                                                 ---------   ---------
  Cash and cash equivalents at end of period     $ 160,550   $  68,517
                                                 =========   =========

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Nabi Biopharmaceuticals

Nabi Biopharmaceuticals
          Investor Relations
          301-770-3099
          www.nabi.com